title: Everolimus for cardiac allograft vasculopathy--every patient, at any time?
authors.affiliation: Cedars-Sinai Heart Institute, Los Angeles, CA 90048, USA.
authors.forename: Jignesh K
authors.initials: JK
authors.lastname: Patel
authors.forename: Jon A
authors.initials: JA
authors.lastname: Kobashigawa
mesh_terms: D001379:Azathioprine / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D049109:Cell Proliferation / Q000187:drug effects; D018450:Disease Progression; D004359:Drug Therapy, Combination; D000068338:Everolimus; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015994:Incidence; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D012307:Risk Factors; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D014652:Vascular Diseases / Q000453:epidemiology* / Q000517:prevention & control*
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D000068338:Everolimus; D009173:Mycophenolic Acid; D001379:Azathioprine; D020123:Sirolimus